neurologia

Alzheimer’s Drug Discovery Foundation – Prevention pipeline

Through its Prevention beyond the pipeline Program,The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Duration: Multi-year Average award: Up to $3,000,000 for clinical trials based on stage …

Alzheimer’s Drug Discovery Foundation – Prevention pipeline Leggi tutto »

Covid, l’impatto sul cervello. Lo studio dell’Università degli Studi di Brescia

Una sindrome neurologica postinfezione da coronavirus: così il cervello diventa uno dei ‘bersagli’ principali del virus SarsCov2. Lo dimostrano i dati dello studio Covid Next dell’Università di Brescia e dell’Istituto Neurologico Besta di Milano, pubblicati sulla rivista Neurological Sciences e discussi durante il primo Webinar del web forum internazionale ‘Pills of Psychiatry and Neurology 2021’ …

Covid, l’impatto sul cervello. Lo studio dell’Università degli Studi di Brescia Leggi tutto »

Alzheimer’s Drug Discovery Foundation – Drug Development Program

Through its Drug Development Program the ADDF seeks to support in vivo preclinical studies that advance lead molecules developed for Alzheimer’s disease and related dementias to IND-enabling studies. The proposed studies should be structured to deliver a compound with strong potential for clinical and commercial application. Drug mechanisms or modes of action: Novel drug mechanisms and …

Alzheimer’s Drug Discovery Foundation – Drug Development Program Leggi tutto »

Alzheimer’s Drug Discovery Foundation – Neuroimaging and CSF Biomarker development program

Given the pathological heterogeneity of Alzheimer’s disease and related dementias, new biomarkers are needed to more accurately characterize specific underlying pathophysiology. This RFP seeks to support the development of CSF and neuroimaging biomarkers for multiple contexts of use (see below) that include but are not limited to: Demonstrate target engagement for novel therapeutics Biomarkers that …

Alzheimer’s Drug Discovery Foundation – Neuroimaging and CSF Biomarker development program Leggi tutto »

Alzheimer’s Drug Discovery Foundation – Prevention beyond the pipeline

Through its Prevention beyond the pipeline Program, the ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Duration: One year for epidemiological analyses Varies (multi-year) for clinical trials Average award: $50,000-$100,000 for epidemiological analyses …

Alzheimer’s Drug Discovery Foundation – Prevention beyond the pipeline Leggi tutto »

Alzheimer’s Drug Discovery Foundation – Neuroimaging and CSF Biomarker development program

Given the pathological heterogeneity of Alzheimer’s disease and related dementias, new biomarkers are needed to more accurately characterize specific underlying pathophysiology. This RFP seeks to support the development of CSF and neuroimaging biomarkers for multiple contexts of use (see below) that include but are not limited to: Clearly demonstrate target engagement for novel therapeutics The …

Alzheimer’s Drug Discovery Foundation – Neuroimaging and CSF Biomarker development program Leggi tutto »

neurologia covid-19

COVID e neurologia “Covid-19 killer per il cervello. Danni al 30% dei pazienti”

Il 23 marzo scorso ha aperto al Civile il primo centro Neuro-Covid in Italia, dedicato ai pazienti che manifestano sintomi da disturbi mentali, crisi epilettiche o forti mal di testa e che sono risultati positivi al virus. Secondo uno studio del prof. Alessandro Padovani, alcuni pazienti manifestano sintomi come il delirio ancora prima di presentare …

COVID e neurologia “Covid-19 killer per il cervello. Danni al 30% dei pazienti” Leggi tutto »

Alzheimer’s Drug Discovery Foundation – Drug Development Program

Through its Drug Development Program the ADDF seeks to support develop therapeutics for Alzheimr’s disease and related dementias. Thsi program focuses on building preclinical evidence in animal models and on adavncing leas molecules to the clincal candidate selection stage. The propose studies shoudl have a high probability or reaching IND-enabling stuides within two years. Current …

Alzheimer’s Drug Discovery Foundation – Drug Development Program Leggi tutto »

Torna su